earnings
confidence high
sentiment positive
materiality 0.80
Edwards Q3 sales rise 14.7% to $1.55B; raises FY EPS guidance to $2.56-$2.62
Edwards Lifesciences Corp
2025-Q3 EPS reported
$1.67
revenue$4,498,000,000
- Q3 sales $1.55B (+14.7% YoY); adjusted EPS $0.67 vs $0.50 GAAP.
- TAVR sales $1.15B (+12.4%); TMTT sales $145.2M (+59.3%).
- Raised FY2025 adjusted EPS guidance to $2.56-$2.62 from high end of $2.45-$2.55.
- Raised TAVR sales growth guidance to 7-8% from 6-7%; total sales growth to high end of 9-10%.
- Board increased share repurchase authorization to $2.1B.